Effect of palm oil (Elaeis guineensis) tocotrienols on mesenteric adipose tissue deposition and the expression of 11β-hydroxysteroid dehydrogenase type 1 enzyme (11β-HSD1) in adrenalectomized rats treated with dexamethasone

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Objectives. A study was done to investigate the effect of palm oil (Elaeis guineensis) tocotrienols on (1) rats mesenteric adipose tissue deposition (2) and 11ß-HSD1 enzyme expression in mesenteric adipocyte. There is a necessity to find an inhibitor for the 11ß-HSD1 enzyme which enhances the proliferation of mesenteric adipocyte tissue therefore curbing the onset of metabolic syndrome. Materials and Methods. A total of 35 male Spraque Dawley rats were divided into 5 different groups, i.e., a baseline control group (n=7), a sham operated group (n=7) and three experimental adrenalectomised groups (ADR) (n=21). Each of the experimental ADR group was given intramuscular dexamethasone (Dexa) with a dose of 120 μg/kg after 2 weeks post adrenalectomy and were divided into adrenalectomised control (n=7), Glycyrrhizic acid (GCA) treated (dose=120 mg/kg/day; n=7) and Palm Tocotrienol treated (dose=60 mg/kg/day; n=7) groups. These various treatments were given 6 days a week for 8 weeks via gastric gavage (following 2 weeks of adrenalectomy). Data is expressed as mean ± standard error mean (SEM), compared to each other using one-way analysis-of-variance (ANOVA) followed by Tukey's post hoc test and then a t-test. Results. The results show that palm tocotrienol tend to slightly increase mesenteric adipose tissue deposition in rats. However, palm tocotrienol was also found to have potential in inhibiting the expression of 11β-HSD1 enzyme in mesenteric adipocytes. Conclusion. This study suggests palm tocotrienol inhibits 11β-HSD1 enzyme expression and activity.

Original languageEnglish
Pages (from-to)99-104
Number of pages6
JournalClinica Terapeutica
Volume166
Issue number3
DOIs
Publication statusPublished - 16 Nov 2015

Fingerprint

Tocotrienols
11-beta-Hydroxysteroid Dehydrogenases
Dexamethasone
Adipose Tissue
Enzymes
Adipocytes
Adrenalectomy
Glycyrrhizic Acid
palm oil
Stomach
Analysis of Variance
Control Groups

Keywords

  • 11β-HSD1
  • Glucocorticoids
  • Metabolic syndrome
  • Visceral adiposecorticoid
  • Visceral obesity

ASJC Scopus subject areas

  • Medicine(all)

Cite this

@article{040f1c50d540413d81c5f065c0d3d78b,
title = "Effect of palm oil (Elaeis guineensis) tocotrienols on mesenteric adipose tissue deposition and the expression of 11β-hydroxysteroid dehydrogenase type 1 enzyme (11β-HSD1) in adrenalectomized rats treated with dexamethasone",
abstract = "Objectives. A study was done to investigate the effect of palm oil (Elaeis guineensis) tocotrienols on (1) rats mesenteric adipose tissue deposition (2) and 11{\ss}-HSD1 enzyme expression in mesenteric adipocyte. There is a necessity to find an inhibitor for the 11{\ss}-HSD1 enzyme which enhances the proliferation of mesenteric adipocyte tissue therefore curbing the onset of metabolic syndrome. Materials and Methods. A total of 35 male Spraque Dawley rats were divided into 5 different groups, i.e., a baseline control group (n=7), a sham operated group (n=7) and three experimental adrenalectomised groups (ADR) (n=21). Each of the experimental ADR group was given intramuscular dexamethasone (Dexa) with a dose of 120 μg/kg after 2 weeks post adrenalectomy and were divided into adrenalectomised control (n=7), Glycyrrhizic acid (GCA) treated (dose=120 mg/kg/day; n=7) and Palm Tocotrienol treated (dose=60 mg/kg/day; n=7) groups. These various treatments were given 6 days a week for 8 weeks via gastric gavage (following 2 weeks of adrenalectomy). Data is expressed as mean ± standard error mean (SEM), compared to each other using one-way analysis-of-variance (ANOVA) followed by Tukey's post hoc test and then a t-test. Results. The results show that palm tocotrienol tend to slightly increase mesenteric adipose tissue deposition in rats. However, palm tocotrienol was also found to have potential in inhibiting the expression of 11β-HSD1 enzyme in mesenteric adipocytes. Conclusion. This study suggests palm tocotrienol inhibits 11β-HSD1 enzyme expression and activity.",
keywords = "11β-HSD1, Glucocorticoids, Metabolic syndrome, Visceral adiposecorticoid, Visceral obesity",
author = "K. Azwan and Farihah Suhaimi and Fairus Ahmad and {Mohd Ramli}, {Elvy Suhana}",
year = "2015",
month = "11",
day = "16",
doi = "10.7417/CT.2015.1837",
language = "English",
volume = "166",
pages = "99--104",
journal = "Clinica Terapeutica",
issn = "0009-9074",
publisher = "Societa Editrice Universo",
number = "3",

}

TY - JOUR

T1 - Effect of palm oil (Elaeis guineensis) tocotrienols on mesenteric adipose tissue deposition and the expression of 11β-hydroxysteroid dehydrogenase type 1 enzyme (11β-HSD1) in adrenalectomized rats treated with dexamethasone

AU - Azwan, K.

AU - Suhaimi, Farihah

AU - Ahmad, Fairus

AU - Mohd Ramli, Elvy Suhana

PY - 2015/11/16

Y1 - 2015/11/16

N2 - Objectives. A study was done to investigate the effect of palm oil (Elaeis guineensis) tocotrienols on (1) rats mesenteric adipose tissue deposition (2) and 11ß-HSD1 enzyme expression in mesenteric adipocyte. There is a necessity to find an inhibitor for the 11ß-HSD1 enzyme which enhances the proliferation of mesenteric adipocyte tissue therefore curbing the onset of metabolic syndrome. Materials and Methods. A total of 35 male Spraque Dawley rats were divided into 5 different groups, i.e., a baseline control group (n=7), a sham operated group (n=7) and three experimental adrenalectomised groups (ADR) (n=21). Each of the experimental ADR group was given intramuscular dexamethasone (Dexa) with a dose of 120 μg/kg after 2 weeks post adrenalectomy and were divided into adrenalectomised control (n=7), Glycyrrhizic acid (GCA) treated (dose=120 mg/kg/day; n=7) and Palm Tocotrienol treated (dose=60 mg/kg/day; n=7) groups. These various treatments were given 6 days a week for 8 weeks via gastric gavage (following 2 weeks of adrenalectomy). Data is expressed as mean ± standard error mean (SEM), compared to each other using one-way analysis-of-variance (ANOVA) followed by Tukey's post hoc test and then a t-test. Results. The results show that palm tocotrienol tend to slightly increase mesenteric adipose tissue deposition in rats. However, palm tocotrienol was also found to have potential in inhibiting the expression of 11β-HSD1 enzyme in mesenteric adipocytes. Conclusion. This study suggests palm tocotrienol inhibits 11β-HSD1 enzyme expression and activity.

AB - Objectives. A study was done to investigate the effect of palm oil (Elaeis guineensis) tocotrienols on (1) rats mesenteric adipose tissue deposition (2) and 11ß-HSD1 enzyme expression in mesenteric adipocyte. There is a necessity to find an inhibitor for the 11ß-HSD1 enzyme which enhances the proliferation of mesenteric adipocyte tissue therefore curbing the onset of metabolic syndrome. Materials and Methods. A total of 35 male Spraque Dawley rats were divided into 5 different groups, i.e., a baseline control group (n=7), a sham operated group (n=7) and three experimental adrenalectomised groups (ADR) (n=21). Each of the experimental ADR group was given intramuscular dexamethasone (Dexa) with a dose of 120 μg/kg after 2 weeks post adrenalectomy and were divided into adrenalectomised control (n=7), Glycyrrhizic acid (GCA) treated (dose=120 mg/kg/day; n=7) and Palm Tocotrienol treated (dose=60 mg/kg/day; n=7) groups. These various treatments were given 6 days a week for 8 weeks via gastric gavage (following 2 weeks of adrenalectomy). Data is expressed as mean ± standard error mean (SEM), compared to each other using one-way analysis-of-variance (ANOVA) followed by Tukey's post hoc test and then a t-test. Results. The results show that palm tocotrienol tend to slightly increase mesenteric adipose tissue deposition in rats. However, palm tocotrienol was also found to have potential in inhibiting the expression of 11β-HSD1 enzyme in mesenteric adipocytes. Conclusion. This study suggests palm tocotrienol inhibits 11β-HSD1 enzyme expression and activity.

KW - 11β-HSD1

KW - Glucocorticoids

KW - Metabolic syndrome

KW - Visceral adiposecorticoid

KW - Visceral obesity

UR - http://www.scopus.com/inward/record.url?scp=84947087793&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84947087793&partnerID=8YFLogxK

U2 - 10.7417/CT.2015.1837

DO - 10.7417/CT.2015.1837

M3 - Article

VL - 166

SP - 99

EP - 104

JO - Clinica Terapeutica

JF - Clinica Terapeutica

SN - 0009-9074

IS - 3

ER -